<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05799352</url>
  </required_header>
  <id_info>
    <org_study_id>P2018/227</org_study_id>
    <nct_id>NCT05799352</nct_id>
  </id_info>
  <brief_title>Effects of Endoscopic Lung Volume Reduction on Diaphragm Function and Conformation</brief_title>
  <official_title>Effects of Endoscopic Lung Volume Reduction on Diaphragm Function and Conformation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Erasme University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Erasme University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Chronic obstructive lung disease (COPD) is a common disease that is frequently complicated by&#xD;
      hyperinflation. The resulting increase in lung volume impairs the diaphragmatic function&#xD;
      because of a shortening of the diaphragmatic fibers and an increase in the radius of&#xD;
      curvature of the diaphragmatic domes. Lung volume reduction surgery (LVRS) has already shown&#xD;
      an improvement in diaphragmatic function that could be explained by a change of the diaphragm&#xD;
      conformation. More recently, endoscopic lung volume reduction (ELVR) has shown benefits in&#xD;
      terms of respiratory function, exercise capacity and quality of life, but the mechanisms of&#xD;
      these improvements are poorly understood. Therefore, we aim to evaluate the evolution of the&#xD;
      diaphragmatic function and the changes in diaphragmatic conformation after unilateral ELVR.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 1, 2019</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Before and after study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Transdiaphragmatic pressure</measure>
    <time_frame>before until 3 months after the valves insertion</time_frame>
    <description>evaluate the difference in diaphragmatic function, assessed by the transdiaphragmatic pressure, before and 3 months after unilateral valves setting</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Diaphragmatic conformation</measure>
    <time_frame>before until 3 months after the valves insertion</time_frame>
    <description>evaluate the change of the diaphragm conformation, by measuring diaphragmatic fibers length in several planes, diaphragmatic area and radius of curvature, before and 3 months after unilateral ELVR.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>COPD</condition>
  <arm_group>
    <arm_group_label>Endoscopic lung volume reduction</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All the patients will have endobronchial valves insertion. We will evaluate before and 3 months after the evolution of the diaphragmatic strength and conformation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Endoscopic lung volume reduction</intervention_name>
    <description>a prospective monocentric study on hyperinflated COPD patients without collateral ventilation. Patients were evaluated before and 3 months after unilateral ELVR by transdiaphragmatic pressure (Pdi) measured at the functional residual capacity (FRC) after magnetic phrenic stimulation and by high-resolution computed tomography at the FRC allowing 3D modelling of the diaphragm for measurements of fibers length, length of the zone of apposition and radius of curvature of the diaphragmatic domes.</description>
    <arm_group_label>Endoscopic lung volume reduction</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  valves insertion&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  TLVR &lt; 50 %&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Olivier Taton</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpital Erasme, Université Libre de Brussels, Brussels, Belgium</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Olivier Taton</last_name>
    <phone>025553943</phone>
    <email>olivier.taton@hubruxelles.be</email>
  </overall_contact>
  <location>
    <facility>
      <name>Erasme Hospital</name>
      <address>
        <city>Brussels</city>
        <zip>1070</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olivier Taton, Resident</last_name>
      <phone>025553943</phone>
      <email>olivier.taton@erasme.ulb.ac.be</email>
    </contact>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>March 2023</verification_date>
  <study_first_submitted>March 23, 2023</study_first_submitted>
  <study_first_submitted_qc>March 23, 2023</study_first_submitted_qc>
  <study_first_posted type="Actual">April 5, 2023</study_first_posted>
  <last_update_submitted>March 23, 2023</last_update_submitted>
  <last_update_submitted_qc>March 23, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">April 5, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Erasme University Hospital</investigator_affiliation>
    <investigator_full_name>Olivier Taton</investigator_full_name>
    <investigator_title>Doctor</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

